Phase II trial of trastumab and weekly paclitaxel for breast cancer. -Japan Breast Cancer Research Network (JBCRN) Trial

Phase II trial of trastumab and weekly paclitaxel for breast cancer. -Japan Breast Cancer Research Network (JBCRN) Trial - trastumab and weekly paclitaxel for breast cancer.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004819

Enrollment

Registered

2011-02-01

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic breast cancer

Interventions

abraxane and paclitaxel

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Patient should be daignose metastatic breast cancer 2 The metastatic size should be more than 10 mmm.

Exclusion criteria

Exclusion criteria: 1) Patient had already treated with palitaxel or trastumab. 2) anaphyaxy of durg 3) pregnant condition

Design outcomes

Primary

Measure	Time frame
response	—

Secondary

Measure	Time frame
safety	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026